Becton Dickinson succeeds under heightened inequitable conduct standard
Becton Dickinson has prevailed against Therasense under the heightened inequitable conduct standard – defying the notion that the doctrine had been rendered obsolete by the Federal Circuit
In a ruling issued yesterday by the Northern District of California, Judge William Alsup found patent 5,820,551 owned by the medical device company Abbott Diabetes Care (formerly Therasense) invalid due to inequitable conduct.
The finding is especially harsh,...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.